The relief rally seen in the markets in March 2025, according to a Kotak Institutional Equities (KIE) report was \u2018an odd mix of fundamentals and sentiment\u2019. <\/small><\/p>\n\n\n\n
That said, the brokerage expects India\u2019s reasonable macroeconomic situation, expectation of normal monsoons and a sluggish global outlook to provide some tailwind for the market. <\/small><\/p>\n\n\n\n
\u201cWe can only speculate on the reasons for this odd rally – some investors may have found value in BFSI stocks, some may have rediscovered value in \u2018narrative\u2019 stocks, others may have taken solace from reducing FPI selling in the past month and inflows in the past week and FPIs may have returned to EMs with the \u2018Trump\u2019 trade disappointing,\u201d the report said.<\/p>\n\n\n\n
KIE expects Nifty EPS of \u20b91007 in FY25E, \u20b91145 in FY26E and 1314 in FY27E with the Nifty trading at 23.3x FY25E, 20.5 x FY26E and 17.9 x FY27E. <\/small><\/p>\n\n\n\n
Fiscal year 2025-26 (FY26), it believes, will likely see more broadbased growth across sectors, with valuations still reasonable for banks and NBFCs.<\/p>\n\n\n\n
Here are the six high conviction stock ideas from KIE that investors can latch on to from a long-term perspective:<\/strong> <\/small><\/p>\n\n\n\n Adani Ports and SEZ – Buy<\/strong><\/p>\n\n\n\n Current market price (CMP): \u20b91,183<\/strong><\/p>\n\n\n\n Fair Value (FV): \u20b91,570<\/strong> <\/small><\/p>\n\n\n\n Adani Ports and SEZ\u00a0reported in-line 10 per cent domestic port Ebitda growth, with guidance for an improved print in Q4, defying seasonality.\u00a0<\/p>\n\n\n\n \u201cWe expect EPS to grow by 19.2 per cent in FY26E & by 10.9 per cent in FY27E,\u201d the report said. The stock is currently trading at 18.0x P\/E FY27E earnings. <\/small><\/p>\n\n\n\n Apollo Hospitals – Buy<\/strong><\/p>\n\n\n\n Current Market Price: \u20b96,616<\/strong><\/p>\n\n\n\n Fair Value: \u20b98,180<\/strong> <\/small><\/p>\n\n\n\n Apollo Hospitals\u00a0reported a fine Q3FY24, with healthy traction across hospitals, offline pharmaceuticals and AHL. The December 2024 quarter was the seventh consecutive quarter of sequential improvement in AHL\u2019s margins.\u00a0\u00a0<\/small><\/p>\n\n\n\n \u201cIts overall bed expansion in FY25-27E is still much lower than almost all peers. While we stay less sanguine on 24\/7, continued sturdy offline FCF should Address any concerns; Maintain Buy.\u201d said Kotak.<\/p>\n\n\n\n Piramal Pharma – Buy<\/strong><\/p>\n\n\n\n CMP: \u20b9225<\/strong><\/p>\n\n\n\n Target price: \u20b9300<\/strong> <\/small><\/p>\n\n\n\n KIE initiated coverage on\u00a0Piramal Pharma\u00a0with \u2018Buy\u2019 with a DCF-based FV of \u20b9300. Piramal Pharma has metamorphosed into a formidable CRDMO player with niche capabilities. The brokerage firm expects higher growth in innovation and differentiated projects.\u00a0\u00a0<\/small><\/p>\n\n\n\n \u201cWe expect earnings to grow by 375.1 per cent in FY26E & grow by 119.1 per cent in FY27E. The stock is currently trading at a valuation of 54.9x P\/E FY27E EPS,\u201d it said. <\/small><\/p>\n\n\n\n Union Bank – Buy<\/strong><\/p>\n\n\n\n CMP: \u20b9126<\/strong><\/p>\n\n\n\n Target Price: \u20b9155<\/strong> <\/small><\/p>\n\n\n\n \u201cUnion Bank\u00a0of India had hosted an analyst meet to discuss the outlook for the bank. We came out of the meeting with a positive outlook on asset quality (delinquencies and bad loan recoveries) for the bank,\u201d the Kotak report said.\u00a0<\/p>\n\n\n\n While Net Interest Margin (NIM) and business growth might be weak in the medium term, the bank has room to preserve profitability in a healthy range through the lever on credit cost. Given the inexpensive valuations, we maintain \u2018Buy\u2019 with an unchanged fair value, it said. <\/small><\/p>\n\n\n\n Cummins India – Buy<\/strong><\/p>\n\n\n\n CMP: \u20b93,052<\/strong><\/p>\n\n\n\n Fair Value: \u20b93,700<\/strong> <\/small><\/p>\n\n\n\n According to KIE, Cummins\u2019 sharp revenue beat reaffirms the health of end markets, strong execution capabilities and competitive positioning. Central Pollution Control Board (CPCB) IV being more of a medium-term opportunity versus a near-term threat. The company also benefited on accounts of higher localization & meaningful financial leverage.<\/p>\n\n\n\n \u201cWe believe that Cummins would be less hit on bottom-line profitability. We marginally cut estimates by 2-3 per cent & revise fair value (FV) to \u20b93,700 (\u20b93,800 earlier), Buy stays,\u201d the brokerage said. <\/small><\/p>\n\n\n\n Amber Enterprises – Add<\/strong><\/p>\n\n\n\n CMP: \u20b97,211<\/strong><\/p>\n\n\n\n Target Price: \u20b97,811<\/strong> <\/small><\/p>\n\n\n\n According to KIE, there are early signs of a favorable summer season for the room AC category, given the IMD forecasts above-normal maximum temperatures during Mar-May 2025 period. <\/small><\/p>\n\n\n\n \u201cWe expect revenues to see a CAGR of 27 per cent over FY2024-27E, driven by growth in components, electronics and Sidwal segments. We expect earnings per share (EPS) to grow by 72.4 per cent in FY26E and 26.5 per cent in FY27E. We revise our estimates by 1-2 per cent up and raise FV to \u20b97,800 from \u20b97,720; retain Add,\u201d the brokerage said.<\/p>\n\n\n\n Eqwires Research Analyst<\/a><\/strong><\/p>\n\n\n\n Top-notch SEBI registered research analyst<\/a><\/strong><\/p>\n\n\n\n Best SEBI registered Intraday tips provider <\/a><\/strong><\/p>\n\n\n\n info@eqwires.com<\/strong><\/a><\/p>\n\n\n\n Telegram <\/a>| Facebook <\/a>| Instagram<\/a><\/strong><\/p>\n\n\n\n Call: +91 9624421555 \/ +91 9624461555<\/em><\/strong><\/p>\n\n\n\n www.eqwires.com<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":" The relief rally seen in the markets in March 2025, according to a Kotak Institutional Equities (KIE) report was \u2018an odd mix of fundamentals and sentiment\u2019. That said, the brokerage expects India\u2019s reasonable macroeconomic situation, expectation of normal monsoons and a sluggish global outlook to provide some tailwind for the market. \u201cWe can only speculate on the reasons for this odd rally – some investors may have found value in BFSI stocks, some may have … Continue reading “Adani Ports, Piramal Pharma: 6 must have stocks to beat the markets”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":3980,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[74],"tags":[],"class_list":["post-3978","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-sebi-registered-advisory-company"],"_links":{"self":[{"href":"https:\/\/www.eqwires.com\/tutorials\/wp-json\/wp\/v2\/posts\/3978","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.eqwires.com\/tutorials\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.eqwires.com\/tutorials\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.eqwires.com\/tutorials\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.eqwires.com\/tutorials\/wp-json\/wp\/v2\/comments?post=3978"}],"version-history":[{"count":1,"href":"https:\/\/www.eqwires.com\/tutorials\/wp-json\/wp\/v2\/posts\/3978\/revisions"}],"predecessor-version":[{"id":3981,"href":"https:\/\/www.eqwires.com\/tutorials\/wp-json\/wp\/v2\/posts\/3978\/revisions\/3981"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.eqwires.com\/tutorials\/wp-json\/wp\/v2\/media\/3980"}],"wp:attachment":[{"href":"https:\/\/www.eqwires.com\/tutorials\/wp-json\/wp\/v2\/media?parent=3978"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.eqwires.com\/tutorials\/wp-json\/wp\/v2\/categories?post=3978"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.eqwires.com\/tutorials\/wp-json\/wp\/v2\/tags?post=3978"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}